Germany Human Genetics Market

ID: MRFR/LS/47562-HCR
200 Pages
Nidhi Mandole
Last Updated: April 06, 2026
Germany Human Genetics Market Research Report By Application (Wellness & E-Commerce, Preventive Medicine, Diagnostic & Treatment) andBy Test (NIPT, Carrier Testing, Pharmacogenomic Testing, Karyotype Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, Others) - Growth & Industry Forecast 2025 To 2035
Germany Human Genetics Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)10.8%
2024 Market Size$ 1,986.81 Million
2025 Market Size$ 2,201.39 Million
2035 Market Size$ 6,140.19 Million
Key Players
Illumina
Thermo Fisher Scientific
Roche
Agilent Technologies
QIAGEN
Myriad Genetics
Opportunities
  • Advancements in Bioinformatics
  • Rising Demand for Genetic Testing
  • Government Initiatives and Funding
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Application (USD Million)
      1. 4.1.1 Wellness & E-Commerce
      2. 4.1.2 Preventive Medicine
      3. 4.1.3 Diagnostic & Treatment
    2. 4.2 Construction, BY Test (USD Million)
      1. 4.2.1 NIPT
      2. 4.2.2 Carrier Testing
      3. 4.2.3 Pharmacogenomic Testing
      4. 4.2.4 Karyotype Testing
      5. 4.2.5 Thrombophilia Testing
      6. 4.2.6 Septin 9 Biomarker Testing
      7. 4.2.7 NGS
      8. 4.2.8 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Illumina (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Thermo Fisher Scientific (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Agilent Technologies (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 QIAGEN (DE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Myriad Genetics (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 BGI Genomics (CN)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Genomatix (DE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 PerkinElmer (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 GERMANY MARKET ANALYSIS BY APPLICATION
    3. 6.3 GERMANY MARKET ANALYSIS BY TEST
    4. 6.4 KEY BUYING CRITERIA OF CONSTRUCTION
    5. 6.5 RESEARCH PROCESS OF MRFR
    6. 6.6 DRO ANALYSIS OF CONSTRUCTION
    7. 6.7 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    8. 6.8 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    9. 6.9 SUPPLY / VALUE CHAIN: CONSTRUCTION
    10. 6.10 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
    11. 6.11 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Million)
    12. 6.12 CONSTRUCTION, BY TEST, 2024 (% SHARE)
    13. 6.13 CONSTRUCTION, BY TEST, 2024 TO 2035 (USD Million)
    14. 6.14 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.2.2 BY TEST, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Germany Human Genetics Market Segmentation

Germany Human Genetics Market By Application (USD Million, 2025-2035)

  • Wellness & E-Commerce
  • Preventive Medicine
  • Diagnostic & Treatment

Germany Human Genetics Market By Test (USD Million, 2025-2035)

  • NIPT
  • Carrier Testing
  • Pharmacogenomic Testing
  • Karyotype Testing
  • Thrombophilia Testing
  • Septin 9 Biomarker Testing
  • NGS
  • Others
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.